The global biomarker-based immunoassays market, valued at USD 5.29 billion in 2024, is projected to grow at a CAGR of 5.3% from 2025 to 2034. This growth is driven by advancements in immunoassay technologies, increasing prevalence of chronic diseases, and a growing emphasis on personalized medicine. The market is witnessing significant contributions from leading countries, each playing a...
Biomarker testing is becoming an increasingly important component of modern healthcare, supporting earlier disease detection, personalized treatment selection, and improved monitoring of therapeutic outcomes. Advances in molecular diagnostics, genomics, proteomics, and data-driven testing platforms are expanding the clinical value of these tools across multiple disease areas.
The Biomarker...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)